| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
24039 |
| Drug |
Sodium Zirconium Cyclosilicate |
| Brand |
Lokelma® |
| Indication |
Sodium Zirconium Cyclosilicate is indicated for the treatment of hyperkalaemia in adult patients. |
| Rapid review commissioned |
01/10/2024 |
| Rapid review completed |
06/11/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost-effectiveness of SZC for this indication compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
27/11/2024 |
| Pre-submission consultation with Applicant |
05/03/2025 |
| Full submission received from Applicant |
04/09/2025 |
